Io Therapeutics, Inc., presented today results from studies of IRX4204, the company’s phase II clinical development stage, highly selective RXR nuclear receptor agonist compound, supporting its potential use for treatment of amyotrophic lateral sclerosis 16-07-2024, 20:26

Media Advisory: Global Cybersecurity Experts Return for the Third Annual Fortinet Security Summit and Tech Expo at the Fortinet Championship Golf Tournament 28-06-2023, 20:00

Philips program developing AI-powered ultrasound to expand access to maternal health receives major funding boost 7-11-2023, 21:00